Nah just a nominee company just shifting shares between funds. Whether for end of year reporting, or to accept the EAR TKO offer not sure. Cdchi1
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress